Common Skin Reactions with Kesimpta
Kesimpta (ofatumumab), used for relapsing multiple sclerosis, causes injection-site reactions in most patients. These include redness, swelling, itching, pain, and bruising at the injection site, typically mild to moderate and decreasing after the first doses.[1][2]
How Often Do They Occur?
About 91% of patients experience local skin reactions. In clinical trials:
- Injection-site reactions: 86.6% (vs. 48.1% with Aubagio).
- Most resolve within days; serious cases are rare (<1%).[1][3]
Why Do These Reactions Happen?
Kesimpta is self-injected subcutaneously, triggering local immune responses like inflammation from the monoclonal antibody. Pre-injection techniques (rotating sites, room-temperature drug) reduce severity.[2][4]
Rarer or Serious Skin Issues
Hypersensitivity reactions (rash, urticaria, angioedema) occur in 1-5% of patients, sometimes with systemic symptoms. Discontinue if anaphylaxis suspected. No increased risk of severe cutaneous reactions like Stevens-Johnson syndrome in trials.[1][3]
Tips to Manage Reactions
- Apply cool compresses post-injection.
- Avoid scratching; use antihistamines for itching if needed.
- Report persistent reactions to a doctor—dose adjustments rarely required.[2][4]
Comparison to Other MS Drugs
Kesimpta has higher local reactions than oral Aubagio but similar to other injectables like Mavenclad. Long-term data shows reactions fade over 1-2 years.[3]
[1]: Kesimpta Prescribing Information, Novartis, 2023. https://www.kesimpta.com/
[2]: FDA Label for Kesimpta (ofatumumab), 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761033s000lbl.pdf
[3]: ASCLEPIOS I/II Trials, Lancet 2020. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31791-2/fulltext
[4]: Multiple Sclerosis Association of America Patient Guide. https://mymsaa.org/